Company

Ridge Biotechnologies, Inc.

Ridge Biotechnologies uses AI to design enzymes and targeted drug delivery technologies.

About

Founded in 2024 and based in Palo Alto, US, Ridge Biotechnologies uses AI to design enzymes and targeted drug technologies. Its products include NativeLink enzymes for protein and peptide modification and ProTrigger linkers for therapeutic payload delivery. In September 2026, the company raised USD 38 million in seed funding led by Dimension Management, Sutter Hill Ventures and Overlap Holdings to scale its platforms and advance discovery programs.

2Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in